Radio and PodcastLive Radio & PodcastsScience & Medicine
147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension
147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension is an episode from...
About This Episode
147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension is an episode from New FDA Approvals. T...
Podcast
This episode belongs to New FDA Approvals.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published May 30, 2018, 13:48 long, audio available.
Related Episodes
Continue listening to more episodes from New FDA Approvals.